WuXi XDC, a premier contract research, development, and manufacturing organization (CRDMO) based in China and specializing in the ADC and bioconjugate sector, has adopted an advanced labeling solution from Schreiner MediPharm to support clinical trials for a novel antibody drug conjugate (ADC). Designed to protect light-sensitive active ingredients while securely blinding the drug, Schreiner MediPharm’s Light-Protect-Label addresses the unique challenges of ADC formulations.
